Caris Life Sciences ® (Caris), a leading next-generation AI TechBio company and precision medicine pioneer, today announced ...
EMERALD-3: Phase III trial of IMFINZI ® (durvalumab) in combination with IMJUDO ® (tremelimumab-actl), with or without lenvatinib, and transarterial chemoembolization (TACE) in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results